Form 4: 4D Molecular Therapeutics CEO Granted Stock Options

4D Molecular Therapeutics' CEO, David Kirn, was granted 750,000 stock options with a $9.88 exercise price, vesting over four years.

Summary

• David Kirn, Chief Executive Officer and Director of 4D Molecular Therapeutics, Inc. (FDMT), was granted 750,000 stock options.
• The stock options have an exercise price of $9.88 per share.
• The earliest transaction date for this grant is March 25, 2026.
• The options will vest as to 1/48th of the underlying shares on each monthly anniversary of March 25, 2026, the Vesting Commencement Date.
• Full vesting (100%) will occur on the fourth anniversary of the Vesting Commencement Date, provided Mr. Kirn remains a service provider to the company.
• The expiration date for these stock options is March 24, 2036.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it signifies continued executive commitment and aligns management's financial interests with long-term shareholder value, which is generally well-received by investors.

Positives

• The grant of stock options to the CEO aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The significant number of options (750,000) indicates a substantial commitment to the CEO's continued leadership and contribution.

Future Outlook

The vesting schedule of the stock options, extending over four years from March 25, 2026, indicates an expectation of David Kirn's continued service as a key executive for 4D Molecular Therapeutics, Inc. for the foreseeable future.

Industry Context

StockSavvy.ai notes that the grant of stock options is a common form of executive compensation in the biotechnology and pharmaceutical sectors, particularly for CEOs of growth-oriented companies like 4D Molecular Therapeutics. This practice aims to align executive incentives with long-term shareholder value creation, a standard approach across the industry.

Comparison to Industry Standards

• Executive stock option grants are a standard component of compensation packages for CEOs in the biotech industry, comparable to practices at companies such as Sarepta Therapeutics or Alnylam Pharmaceuticals, where long-term incentives are crucial for retaining talent and driving innovation.
• The four-year vesting schedule is typical for executive equity awards, mirroring common structures seen at peer companies to ensure sustained commitment and performance over a multi-year horizon.

Stakeholder Impact

• Shareholders: The grant of stock options to the CEO is intended to align his interests with those of shareholders, potentially leading to enhanced long-term value creation.
• Employees: This type of executive compensation can set a precedent or reflect the company's overall compensation philosophy, potentially influencing other employee incentive programs.

Next Steps

• David Kirn's continued service to the company to fulfill the vesting requirements of the stock options.
• Future Form 4 filings will report any exercises or sales of these options, or other insider transactions by Mr. Kirn.

Key Dates

Keywords

4D Molecular Therapeutics, FDMT, David Kirn, Stock Options, Executive Compensation, Insider Transaction, SEC Form 4, Biotechnology, Gene Therapy